Dr. Beth Rosenwasser, PH.D. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 553 Putnam Rd, Merion Station, PA 19066 Phone: 610-660-0262 |
Ms. Miriam Field, M.S.S. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 515 Howe Rd, Merion Station, PA 19066 Phone: 610-617-0730 Fax: 610-617-4411 |
Dr. Paul J. Potesta, PH.D. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 533 Hamilton Rd, Merion Station, PA 19066 Phone: 610-664-7240 |
News Archive
ExonHit Therapeutics announces today CE marking of AclarusDx, its blood-based test intended to help in the diagnosis of Alzheimer's disease. This gives AclarusDx the status of In Vitro Diagnostic.
Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules.
Will Bondurant decided to get tested for COVID-19 after attending three racial justice demonstrations over a five-day period in San Francisco, where he lives.
Hitachi Software Engineering America, Ltd. and OriGene Technologies, Inc. today announced a co-marketing agreement to jointly promote OriGene's multiplex assays built on Luminex xMAP/Bio-Plex technology and Hitachi Software's MasterPlex software suite for analysis and reporting of multiplex assay data.
Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.
› Verified 4 days ago